By Mari Hansen When a Big Pharma name enters a small biotech, there’s a certain silence. The founders sound suddenly older, the language becomes stagnant, and the science, which had been the loudest thing in the room for years, is now measured in milestones and money. You can almost feel it in the press releases. That’s about how CrossBridge Bio is feeling this month.
A small team at the Texas Medical Center’s innovation hub is realizing that their experiment has just become someone else’s pipeline as Eli Lilly has agreed to purchase the three-year-old Houston startup in a deal worth up to $300 million.
| Key Information | Details |
|---|---|
| Acquiring Company | Eli Lilly and Company |
| Target Company | CrossBridge Bio, Inc. |
| Headquarters of Target | Houston, Texas (Texas Medical Center innovation hub) |
| Founded | 2023 |
| Co-Founder & CEO | Dr. Michael Torres |
| Originating Institution | University of Texas Health Science Center at Houston |
| Lead Asset | CBB-120 — a TROP2-targeting dual-payload ADC |
| Mechanism | TOP1 inhibitor + ATR inhibitor, dual-payload platform |
| Deal Value | Up to $300 million (upfront + milestone) |
| Announcement Date | April 14, 2026 |
| Expected IND Filing | 2026 |
| Earlier Seed Funding | $10 million (2024), led by TMC Venture Fund and CE-Ventures |
| Grant Received | $15 million from Cancer Prevention and Research Institute of Texas |
| Legal Counsel | Cooley LLP |
| Strategic Advisor | Zwick Advisory, LLC |
It wasn’t intended to be a household name, and CrossBridge isn’t. The company was born out of work done by Kyoji Tsuchikama at UTHealth Houston, and for the majority of its brief existence, it has been a lab story: payload stability, linker chemistry, and the little, unglamorous issues that determine whether an antibody-drug conjugate is effective in a patient or quietly fails in a trial. TROP2, a protein found in triple-negative breast, lung, pancreatic, colorectal, and several other tumor types, is the target of its lead candidate, CBB-120. It’s a crowded area. Trodelvy from Gilead is already present. This also applies to the AstraZeneca-Daiichi Sankyo medication Datroway. CrossBridge’s pitch is that when two payloads are delivered simultaneously, they can outmaneuver the obstacles that single-payload ADCs eventually encounter.
It’s really unclear if that works out. No human has yet been exposed to the drug. The preparation of the IND is still ongoing. However, Lilly appears to have concluded that the science is worth a bridge of capital while it investigates.
Interestingly, Lilly has been the cautious one in this category for a long time. Jacob Van Naarden, the company’s president of oncology R&D, expressed open skepticism about the ADC frenzy back in 2023, implying that the field had a tendency to confuse one successful idea for a generation of them. And yet, here we are. In about two years, Lilly has now acquired CrossBridge, Mablink Bioscience, and Emergence Therapeutics. According to PitchBook, there have been sixteen biotech acquisitions since 2023. In 2026, three of them have already completed billion-dollar transactions: Ventyx in January, Orna in February, and Centessa in March. The rhetoric still contains caution. Simply put, the spending no longer shows it.
Meanwhile, Houston is experiencing an unplanned moment. Additionally, Lilly is constructing a $6.5 billion manufacturing facility in the region, which is anticipated to create about 4,000 jobs. The CrossBridge agreement is part of that broader gravitational pull, which is the gradual perception that the city’s medical district is becoming more of a destination rather than a breeding ground for coastal biotech. These days, it’s difficult to ignore how frequently Texas Medical Center’s name appears in deal announcements.
As is often the case, the terms of the CrossBridge acquisition are ambiguous. upfront money plus a milestone payment in the event that a particular development obstacle is overcome. The majority of what you need to know about leverage in the room is revealed by Lilly’s refusal to reveal the split. In the press release, CEO Michael Torres expressed his pride in the team, his anticipation of Lilly’s stewardship, and the customary choreography. There’s no reason to question his sincerity. Seldom do founders sell when they want to.
The question of whether $300 million is modest or generous for what Lilly is purchasing is more difficult to interpret. CBB-120 is a great deal if it works. It’s a standard write-down for a business spending billions elsewhere if it joins the long list of ADCs that appeared elegant in mice but disappointed in patients. Investors appear to think the dual-payload thesis is worth the risk, and Lilly’s willingness to continue writing checks indicates an internal belief that a single mechanism won’t win the next wave of oncology.
The Houston lab continues to operate for the time being. The IND was filed sometime in 2026. As usual, patients with few options are waiting in the background of the story—the part that doesn’t make the press release but is ultimately what counts.